Repligen Corp RGEN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if RGEN is a good fit for your portfolio.
News
-
Repligen Announces CEO Transition Plan
-
Repligen Corporation to Present at Upcoming June Investor Conferences
-
Repligen Corporation to Present at Upcoming May Investor Conferences
-
Repligen Reports First Quarter 2024 Financial Results
-
Repligen to Report First Quarter 2024 Financial Results
-
Repligen Appoints Maggie A. Pax to Board of Directors
-
Big Tech stocks look 'exhausted,' analyst warns. But these 100 'next-gen' Nasdaq names appear poised to take off.
Trading Information
- Previous Close Price
- $125.62
- Day Range
- $123.37–129.86
- 52-Week Range
- $110.45–211.13
- Bid/Ask
- $111.00 / $160.12
- Market Cap
- $6.95 Bil
- Volume/Avg
- 1.2 Mil / 542,240
Key Statistics
- Price/Earnings (Normalized)
- 59.78
- Price/Sales
- 11.51
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 0.21%
Company Profile
Repligen Corp is a global life sciences company. It develops and commercializes innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs. The company's customers include life science companies, global biopharmaceutical companies, and contract manufacturers worldwide. Repligen markets its products globally through a direct commercial organization in the U.S., Europe, and Asia, as well as through strategic partners in select markets. The majority of the company's revenue is generated in North America.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Stock Style Box
- Small Growth
- Total Number of Employees
- 1,783
- Website
- https://www.repligen.com
Comparables
Valuation
|
Metric
|
RGEN
|
CYRX
|
AZTA
|
|---|---|---|---|
Price/Earnings (Normalized) | 59.78 | 15.60 | 115.51 |
Price/Book Value | 3.52 | 1.09 | 1.33 |
Price/Sales | 11.51 | 2.13 | 4.90 |
Price/Cash Flow | 68.54 | — | 60.53 |
Price/Earnings
RGEN
CYRX
AZTA
Financial Strength
|
Metric
|
RGEN
|
CYRX
|
AZTA
|
|---|---|---|---|
Quick Ratio | 5.03 | 10.00 | 4.81 |
Current Ratio | 6.35 | 10.73 | 5.86 |
Interest Coverage | 5.59 | −20.18 | — |
Quick Ratio
RGEN
CYRX
AZTA
Profitability
|
Metric
|
RGEN
|
CYRX
|
AZTA
|
|---|---|---|---|
Return on Assets (Normalized) | 2.94% | −4.67% | −0.57% |
Return on Equity (Normalized) | 3.96% | −9.37% | −0.65% |
Return on Invested Capital (Normalized) | 3.31% | −4.35% | −2.14% |
Return on Assets
RGEN
CYRX
AZTA
Medical Instruments & Supplies Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Intuitive Surgical Inc
ISRG
| Fsffzbjwy | Pnnk | $152.5 Bil | |||
| Becton Dickinson & Co
BDX
| Gpfpztgp | Drcwnw | $67.3 Bil | |||
| Alcon Inc
ALC
| Mfdqgjsl | Spplht | $43.5 Bil | |||
| ResMed Inc
RMD
| Kjhrybpjnj | Yvpmfy | $30.9 Bil | |||
| Coloplast A/S ADR
CLPBY
| Tlpbsblg | Wvy | $27.5 Bil | |||
| West Pharmaceutical Services Inc
WST
| Dycqhjdj | Xfq | $24.6 Bil | |||
| The Cooper Companies Inc
COO
| Glqznfhv | Ycrmzqk | $18.4 Bil | |||
| Baxter International Inc
BAX
| Lhtnbtqx | Ghmrbz | $17.3 Bil | |||
| Hologic Inc
HOLX
| Hzzbnynk | Bgwqfnp | $16.7 Bil | |||
| AptarGroup Inc
ATR
| Xydccpnyv | Zllkfc | $9.7 Bil |